

REMARKS

Claim 13 was cancelled from the present application without prejudice to re-filing the claim in a continuation application. Claims 1 and 14 have been amended to be directed to elected subject matter pursuant to the Examiner's Restriction Requirement. Claims 2 and 14 were amended to independent claim format. Claim 4 was amended to add a period at the end of the sentence. Claims 15 and 22 were amended to correct dependency. No new matter has been added. Claims 1 – 12 and 14 – 24 are currently pending.

35 U.S.C. § 112

Claims 13 – 15 were rejected under 35 U.S.C. § 112, first paragraph. Claim 13 was cancelled from the present application. Therefore, the rejection is moot as to this claim. Claim 14, directed to method of treating and preventing an HCV infection, was amended to independent claim format. Claim 15 was amended to depend from claim 14. Support for claims 14 and 15 is found in the specification at pages 5, and 100 – 105.

Objections


Claims 1, 3-13, 21-24 were objected to because they contain or are dependent on subject matter that has been withdrawn from consideration. Claim 1 has been amended to conform with the Restriction Requirement; dependent claims 3 – 12 and 21 – 24 now reflect the elected subject matter.

Applicants respectfully submit that the application is in condition for allowance. An early consideration and notice of allowance are earnestly solicited.

The Commissioner is hereby authorized to charge any fees required or credit any overpayment to Deposit Account No. 07-1392.

Respectfully submitted,

Dated: June 21, 2007
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398
Telephone: 919-483-2192
Fax: 919-483-7988


Karen L. Prus
Attorney for Applicant
Reg. No. 39,337